General Information of Drug (ID: DM83L5Y)

Drug Name
RIP
Synonyms
beta-D-Ribopyranose; Ribose(Pyranose Form); 7296-60-8; UNII-49X539P7H4; CHEBI:27476; 49X539P7H4; (2R,3R,4R,5R)-oxane-2,3,4,5-tetrol; b-Ribopyranose; 115794-07-5; beta-D-Ribopyranose (9CI); 1ogd; 1drk; 2dri; 1drj; Ribopyranose, beta-D-; SCHEMBL625216; AC1L9B91; CHEMBL1159662; CTK4A9488; ZINC4097544; DB04286; 1577-EP2301533A1; 1577-EP2292630A1; 1577-EP2316459A1; 1577-EP2305808A1; 1577-EP2281563A1; C08353; 1577-EP2270015A1; 31308-EP2311817A1; 31308-EP2308858A1; 31308-EP2274983A1; 31308-EP2311816A1; 31308-EP2292088A1
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 150.13
Logarithm of the Partition Coefficient (xlogp) -2.5
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 5
Chemical Identifiers
Formula
C5H10O5
IUPAC Name
(2R,3R,4R,5R)-oxane-2,3,4,5-tetrol
Canonical SMILES
C1[C@H]([C@H]([C@H]([C@@H](O1)O)O)O)O
InChI
InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3-,4-,5-/m1/s1
InChIKey
SRBFZHDQGSBBOR-TXICZTDVSA-N
Cross-matching ID
PubChem CID
441481
ChEBI ID
CHEBI:27476
CAS Number
7296-60-8
DrugBank ID
DB04286
TTD ID
D0A1RG

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiotensin-converting enzyme (ACE) DTT SLC33A1 2.62E-01 -0.01 -0.06
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors. J Med Chem. 1985 Nov;28(11):1553-5.